AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

FENNEC PHARMACEUTICALS INC. Director's Dealing 2021

Dec 20, 2021

35599_dirs_2021-12-20_a6362b36-7bb5-4898-8b3a-fd75f4c7418e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FENNEC PHARMACEUTICALS INC. (FENC)
CIK: 0001211583
Period of Report: 2021-12-20

Reporting Person: Goel Shubh (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-20	Stock Option (right to buy)	$4.08	A	75000	Acquired	2031-12-20	Common Shares (75000)	Direct
2021-12-20	Restricted Share Unit (right to receive value of a share)	$0	A	37500	Acquired	2031-12-20	Common Shares (37500)	Direct

Footnotes

F1: On December 20, 2021, Shubh Goel was granted an incentive stock option to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.

F2: On December 20, 2021, Shubh Goel was granted restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.

F3: Item vests 100% upon FDA approval of PEDMARKTM.